Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To demonstrate the relative bioavailability of Diclofenac Sodium 75 mg enteric-coated tablets under non-fasting conditions.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical) |
|
| 2 | Experimental | Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical) |
|
| 3 | Active Comparator | Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical) | Drug |
| ||
| Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical) |
| Measure | Description | Time Frame |
|---|---|---|
| Bioequivalence based on AUC and Cmax | 32 days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paul D. Larsen, M.D. | Red River Clinical | Principal Investigator |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals) | Drug |
|
| ID | Term |
|---|---|
| D007249 | Inflammation |
| ID | Term |
|---|---|
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D004008 | Diclofenac |
| ID | Term |
|---|---|
| D010648 | Phenylacetates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided